Format

Send to

Choose Destination
Psychopharmacology (Berl). 2015 Mar;232(5):975-83. doi: 10.1007/s00213-014-3732-x. Epub 2014 Sep 12.

Differentiating the primary reinforcing and reinforcement-enhancing effects of varenicline.

Author information

1
Department of Neuroscience, University of Pittsburgh, A210 Langley Hall, 5th and Ruskin Avenue, Pittsburgh, PA, 15260, USA.

Abstract

RATIONALE:

Varenicline (VAR), a smoking cessation aid that is a partial agonist at nicotinic receptors, mimics the reinforcement-enhancing effects of nicotine. Varenicline, when accompanied by non-drug cues, is self-administered by rats, though it is unclear whether this results from varenicline acting as a primary reinforcer or a reinforcement enhancer of the cues.

OBJECTIVES:

This study sought to disentangle these two potential actions.

METHODS:

Rats were allowed to self-administer intravenous nicotine, saline, or varenicline during 1-h sessions in operant chambers equipped with two levers. Five groups had concurrent access to drug infusions and a moderately reinforcing visual stimulus (VS) for responding on separate levers. Meeting the reinforcement schedule on one lever was reinforced with VAR (0.01, 0.06, 0.1 mg/kg/infusion), nicotine (0.06 mg/kg/infusion), or saline, while meeting the same schedule on the other lever delivered the VS. Additional groups were reinforced for pressing a single "active" lever and received VAR paired with the VS, the VS with response-independent infusions of VAR, or VAR alone (0.1 mg/kg/infusion).

RESULTS:

Rats readily responded for VAR paired with VS on a single lever. However, when VAR was the only reinforcer contingent on a response, rats did not respond more than for saline.

CONCLUSIONS:

These findings show that VAR does not serve as a primary reinforcer in rats at doses that increase responding for non-drug reinforcers. These data are consistent with research showing that the primary reinforcing effects of VAR are weak, at best, and that the primary reinforcing and reinforcement-enhancing actions of nicotinic drugs are pharmacologically distinct.

PMID:
25209677
PMCID:
PMC4326540
DOI:
10.1007/s00213-014-3732-x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center